rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CNTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Piper Sandler Sticks to Its Buy Rating for Context Therapeutics (CNTX)

      Tipranks Press Release.

      Nov 12The Globe and MailCNTX
      Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
      Nov 10Yahoo FinanceCNTX
      Analysts Are Bullish on These Healthcare Stocks: Context Therapeutics (CNTX), Compass Therapeutics (CMPX)

      Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailCMPXCNTX
      New Strong Sell Stocks for October 15th

      Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.

      Oct 15The Globe and MailCNTX
      Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

      CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the P

      Sep 9Yahoo FinanceCNTX

      This is the newest page. Registered accounts read further back.